And third, endothelial oxidative stress, closely linked to the up-regulation of NOX2 in ECs, might be an important mechanism underlying the impairment of type H vessels in the diabetic bone, and NOX2 inhibitors, such as GSK2795039, show potential for clinical therapy of bone diseases in T1DM patients. The gene discussed is CYBB; the disease is type 1 diabetes mellitus.